GNPX vs. GLYC, TLPH, FLGC, LUMO, CMMB, SLGL, BCTX, KPRX, UPC, and KTRA
Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include GlycoMimetics (GLYC), Talphera (TLPH), Flora Growth (FLGC), Lumos Pharma (LUMO), Chemomab Therapeutics (CMMB), Sol-Gel Technologies (SLGL), BriaCell Therapeutics (BCTX), Kiora Pharmaceuticals (KPRX), Universe Pharmaceuticals (UPC), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
GlycoMimetics (NASDAQ:GLYC) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
GlycoMimetics has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500.
GlycoMimetics received 116 more outperform votes than Genprex when rated by MarketBeat users. However, 65.25% of users gave Genprex an outperform vote while only 61.52% of users gave GlycoMimetics an outperform vote.
GlycoMimetics presently has a consensus price target of $10.00, indicating a potential upside of 4,045.94%. Genprex has a consensus price target of $10.00, indicating a potential upside of 437.63%. Given Genprex's higher possible upside, research analysts clearly believe GlycoMimetics is more favorable than Genprex.
Genprex has lower revenue, but higher earnings than GlycoMimetics.
Genprex's return on equity of -88.40% beat GlycoMimetics' return on equity.
In the previous week, GlycoMimetics had 6 more articles in the media than Genprex. MarketBeat recorded 8 mentions for GlycoMimetics and 2 mentions for Genprex. GlycoMimetics' average media sentiment score of 0.43 beat Genprex's score of 0.05 indicating that Genprex is being referred to more favorably in the news media.
75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 11.5% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
GlycoMimetics beats Genprex on 8 of the 14 factors compared between the two stocks.
Get Genprex News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
